SCHEMBL3086154

SCHEMBL3086154

Cn1cc(-c2cnc3ccc(-c4cncc(NS(C)(=O)=O)c4)cc3n2)cn1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FGFR3 P22607 12/20 0.53
KDR P35968 12/20 0.53
MET P08581 1/20 0.52
KCNH2 Q12809 1/20 0.52
NPC1 O15118 1/20 0.48
JAK2 O60674 1/20 0.48
RAB9A P51151 1/20 0.48
FGFR1 P11362 9/20 0.48
FGFR4 P22455 7/20 0.48
FGFR2 P21802 7/20 0.46
PIK3CB P42338 1/20 0.46
CCNC P24863 1/20 0.44
CDK8 P49336 1/20 0.44
FLT3 P36888 2/20 0.44
BRD4 O60885 1/20 0.43
MAPK1 P28482 2/20 0.43
AURKB Q96GD4 1/20 0.43
EGFR P00533 1/20 0.43
PIK3CA P42336 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3091202 0.91 FGFR3 (0.52) FGFR3KDRMETFGFR1FGFR4
SCHEMBL3088144 0.89 FGFR3 (0.50) FGFR3KDRFGFR1FGFR4FGFR2
SCHEMBL3095135 0.89 MET (0.54) FGFR3KDRMETFGFR1FGFR4
SCHEMBL3091107 0.89 LRRK2 (0.48) FGFR3KDRMETKCNH2FGFR1
SCHEMBL3084045 0.88 FGFR3 (0.52) FGFR3KDRFGFR1FGFR4FGFR2
SCHEMBL3094941 0.88 PIK3CA (0.50) FGFR3KDRFGFR1FGFR4FGFR2
SCHEMBL3092451 0.88 FGFR3 (0.49) FGFR3KDRMETFGFR1FGFR4
SCHEMBL3082214 0.88 FGFR3 (0.48) FGFR3KDRMETFGFR1FGFR4
SCHEMBL3090646 0.87 PIK3CB (0.52) FGFR3KDRMETFGFR1FGFR4
SCHEMBL3095088 0.87 MET (0.57) FGFR3KDRMETKCNH2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-09-16 US disclosed
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-09-16 US disclosed
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-09-16 US disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS PIP5K1A, PIK3CB, PIK3CG FGFR3 2690/4885KDR 1697/4885MET 4743/4885
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS PIP5K1A, PIK3CB, PIK3CG FGFR3 2690/4885KDR 1697/4885MET 4743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.